The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected medicines with substantial clinical benefit...
Myeloma NZ
Decision on access criteria for oral COVID-19 treatments
The Access Criteria for the oral antiviral COVID-19 treatments, nirmatrelvir with ritonavir (Paxlovid) and molnupiravir (Lagevrio) has been...
FRAIL-M TRIALS FOR TRANSPLANT INELIGIBLE MYELOMA (PHASE I/II)
Frail-M test
Honoured haematologist and HIV pioneer fears he won’t see action from ‘glacial’ Pharmac in his lifetime.
After New Year's Honours for his work, he now fears could die without seeing a single new myeloma-fighting drug added to those funded by Pharmac,...
COVID-19 information for patients and whānau with cancer.
This link here: Te Aho o Te Kahu - Cancer during COVID-19 contains information for patients and whānau with cancer. Cancer treatment continues at...
Pharmac Review Final Report – Update
In a radio interview today, Health Minister Andrew Little said the final Pharmac Review report will be publicised "in a matter of a few...
Newsletter: Autumn 2022
Dear All, I am writing this today and hearing about the 20,000 plus daily Covid-19 cases being reported which we know is probably half of the real...
Endorsers of the ICBCC Patient Impact Statement
Last Thursday 24 February the ICBCC Policy Strategy Working Group met to discuss on the Policy Strategy to address the specific impact of the...
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG), article of the week
The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to...
CD38 directed therapy shows promise in Multiple Myeloma
Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome...
Australians have limited awareness of blood cancers, – new survey
Australians will not seek help for blood cancer symptoms: survey (thelimbic.com)
Which haematology patients are at higher risk of COVID-19?
Watch this excellent presentation by Dr Rob Weinkove of the Malaghan Institute, courtesy of Leukaemia & Blood Cancer NZ, on ‘COVID-19 and...